Baird downgraded Vor Bio (VOR) to Neutral from Outperform with a price target of 25c, down from $14, after the company announced plans to wind down its clinical and manufacturing operations, beginning immediately, and pivot to looking for strategic alternatives for the business. The update led Baird to downgrade the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: